The I-Mab team from L-R: CFO Jielun Zhu; President Zheru Zhang; Founder and chairman Jingwu Zang; CEO Joan Shen; and chief commercial officer Ivan Yifei Zhu

I-Mab in talks about deals, stake sale to build on $3B Ab­b­Vie al­liance — Bloomberg

A year af­ter I-Mab made head­lines with its $2.9 bil­lion deal li­cens­ing a CD47 drug to Ab­b­Vie, the Chi­nese biotech is re­port­ed­ly hold­ing ear­ly talks with glob­al phar­ma play­ers about part­ner­ships and po­ten­tial in­vest­ment.

The Shang­hai-based, Nas­daq-list­ed com­pa­ny is mulling “clin­i­cal and com­mer­cial co­op­er­a­tion in Chi­na and a po­ten­tial eq­ui­ty stake sale,” Bloomberg re­port­ed, quot­ing peo­ple fa­mil­iar with the mat­ter. Both US and Eu­ro­pean drug­mak­ers are among the suit­ors in­volved in pre­lim­i­nary dis­cus­sions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.